CASI Pharmaceuticals, Inc. — Form D

CASI Pharmaceuticals, Inc. of BEIJING, F4, a company, filed a Form D exempt-offering notice with the SEC on 2026-04-28. The offering totals $5.0M, of which $5.0M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (36)

Showing 25 of 36 people.

NameRoleLocation
Thomas FolinsbeeRelated PersonBeijing, F4
Wei GaoRelated PersonBeijing, F4
Wei-Wu HeRelated PersonRockville, MD
Hai HuangRelated PersonBeijing, F4
James HuangRelated PersonSouth San Francisco, CA
Barbara Krebs-PohlRelated PersonSouth San Francisco, CA
Kun QianRelated PersonBeijing, F4
Zhenbo SuRelated PersonBeijing, F4
Chunhua WangRelated PersonBeijing, F4
Alexander Y. WuRelated PersonRockville, MD
Xuebo ZengRelated PersonBeijing, F4
Wei (Larry) ZhangRelated PersonSouth San Francisco, CA
Wei-Wu HeDirectorRockville, MD
Wei-Wu HeExecutive OfficerRockville, MD
Chunhua Y WangExecutive OfficerBeijing, F4
Wei Y GaoExecutive OfficerBeijing, F4
Alexander Y WuDirectorRockville, MD
Zhenbo SuDirectorBeijing, F4
Hai Y HuangExecutive OfficerBeijing, F4
Kun Y QianExecutive OfficerBeijing, F4
Thomas FolinsbeeDirectorBeijing, F4
Xuebo Y ZengDirectorBeijing, F4
Alexander A ZukiwskiExecutive OfficerRockville, MD
Wei (Larry) Y ZhangExecutive OfficerBeijing, F4
Wei Y. GaoExecutive OfficerBeijing, F4

Other filings by this issuer (4)

FiledFormOfferingSold
2026-02-26D$5.0M$5.0M
2026-01-28D$5.0M$5.0M
2026-01-28D$5.0M$5.0M
2024-07-15D$15.0M$15.0M

More